ImmuCell Balance Sheet Health
Financial Health criteria checks 3/6
ImmuCell has a total shareholder equity of $25.0M and total debt of $12.0M, which brings its debt-to-equity ratio to 47.9%. Its total assets and total liabilities are $43.8M and $18.8M respectively.
Key information
47.9%
Debt to equity ratio
US$11.97m
Debt
Interest coverage ratio | n/a |
Cash | US$978.74k |
Equity | US$24.99m |
Total liabilities | US$18.82m |
Total assets | US$43.81m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IUL's short term assets ($11.5M) exceed its short term liabilities ($4.2M).
Long Term Liabilities: IUL's short term assets ($11.5M) do not cover its long term liabilities ($14.6M).
Debt to Equity History and Analysis
Debt Level: IUL's net debt to equity ratio (44%) is considered high.
Reducing Debt: IUL's debt to equity ratio has increased from 44.9% to 47.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IUL has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: IUL is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.